Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012

Transfusion

Volumn 55, Issue 4, 2015, Pages 709-718

  Harvey, Alexis R ^a   Basavaraju, Sridhar V ^a   Chung, Koo Whang ^a   Kuehnert, Matthew J ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEMOLYTIC TRANSFUSION REACTION; ARTICLE; BLOOD SAFETY; BLOOD SAMPLING; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; DELAYED HEMOLYTIC TRANSFUSION REACTION; DELAYED SEROLOGIC TRANSFUSION REACTION; ERYTHROCYTE TRANSFUSION; FEBRILE NONHEMOLYTIC TRANSFUSION REACTION; HEALTH CARE FACILITY; HUMAN; PATIENT SAFETY; PLASMA TRANSFUSION; PROGRAM EVALUATION; QUALITY CONTROL; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD; TRANSFUSION ASSOCIATED DYSPNEA; TRANSFUSION RELATED ACUTE LUNG INJURY; TRANSFUSION TRANSMITTED INFECTION; UNITED STATES; URBAN AREA; ACUTE LUNG INJURY; ADVERSE EFFECTS; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; COMMUNICABLE DISEASES; INFORMATION PROCESSING; LEUKAPHERESIS; PROCEDURES; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY; TRANSFUSION REACTION; TRANSMISSION; UTILIZATION;

ACUTE LUNG INJURY; BLOOD COMPONENT TRANSFUSION; BLOOD SAFETY; BLOOD TRANSFUSION; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COMMUNICABLE DISEASES; DATA COLLECTION; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; RETROSPECTIVE STUDIES; TRANSFUSION REACTION; UNITED STATES;

EID: 84926505959     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12918     Document Type: Article

References (36)

1. de Vries RR, Faber JC, Strengers PF,; Board of the International Haemovigilance Network. Haemovigilance: an effective tool for improving transfusion practice. Vox Sang 2011; 100: 60-67.
2. Murphy MF, Stanworth SJ, Yazer M,. Transfusion practice and safety: current status and possibilities for improvement. Vox Sang 2011; 100: 46-59.
3. Keller-Stanislawski B, Lohmann A, Gunay S, et al. The German Haemovigilance System-reports of serious adverse transfusion reactions between 1997 and 2007. Transfus Med 2009; 19: 340-349.
4. Giampaolo A, Piccinini V, Catalano L, et al. The first data from the haemovigilance system in Italy. Blood Transfus 2007; 5: 66-74.
5. Stainsby D, Jones H, Asher D, et al.; SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006; 20: 273-282.
6. Robillard P, Nawej KI, Jochem K,. The Quebec hemovigilance system: description and results from the first two years. Transfus Apher Sci 2004; 31: 111-122.
7. Rebibo D, Hauser L, Slimani A, et al. The French Haemovigilance System: organization and results for 2003. Transfus Apher Sci 2004; 31: 145-153.
8. Andreu G, Morel P, Forestier F, et al. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002; 42: 1356-1364.
9. US. Department of Health and Human Services. The 2011 national blood collection and utilization survey report. Washington, DC: Department of Health and Human Services; 2013.
10. US. Food and Drug Administration. Vaccines, Blood & Biologics. Transfusion/donation fatalities. 2013 [cited 2013 Dec 20]. Available from: http://www.fda.gov/biologicsbloodvaccines/safetyavailability/reportaproblem/transfusiondonationfatalities/default.htm
11. Eder AF, Dy BA, Barton J, et al. The American Red Cross Hemovigilance Program: advancing the safety of blood donation and transfusion. Immunohematology 2009; 25: 179-185.
12. The Joint Commission. Sentinel event policy and procedures. 2013 [cited 2013 Dec 20]. Available from: http://www.jointcommission.org/Sentinel-Event-Policy-and-Procedures/
13. US. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDSS). Division of Health Informatics and Surveillance (DHIS), Centers for Disease Control and Prevention; 2013 [cited 2013 Dec 20]. Available from: http://wwwn.cdc.gov/nndss/default.aspx
14. Commonwealth of Massachusetts Department of Public Health Clinical Laboratory Program. Blood bank monthly activity report. 2013 [cited 2013 Dec 20]. Available from: http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/labs/public-health-clinical-lab-blood-banks.html
15. US. Centers for Disease Control and Prevention. National Healthcare Safety Network. 2013 [cited 2013 Dec 20]. Available from: http://www.cdc.gov/nhsn/
16. US. Centers for Disease Control and Prevention. The National Healthcare Safety Network (NHSN) manual: biovigilance component v1.3. Atlanta (GA): Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 2011: 1-30.
17. Pfuntner A, Wier LM, Stocks C,. Most frequent procedures performed in U.S. hospitals, 2011: Statistical Brief #165 Healthcare Cost and Utilization Project (HCUP). Rockville (MD): Agency for Healthcare Research and Quality; 2013.
18. Willaert B, Vo Mai MP, Caldani C,. French haemovigilance data on platelet transfusion. Transfus Med Hemother 2008; 35: 118-121.
19. Moncharmont P, Meyer F,. [Allergic adverse transfusion reactions in paediatrics, a 3-year study]. Transfus Clin Biol 2013; 20: 455-457.
20. Hamzeh-Cognasse H, Damien P, Nguyen KA, et al. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. Transfusion 2014; 54: 613-625.
21. Nogawa M, Naito Y, Chatani M, et al. Parallel comparison of apheresis-collected platelet concentrates stored in four different additive solutions. Vox Sang 2013; 105: 305-312.
22. Semple E, Bowes-Schmidt A, Yi QL, et al. Transfusion reactions: a comparative observational study of blood components produced before and after implementation of semiautomated production from whole blood. Transfusion 2012; 52: 2683-2691.
23. Steinsvag CT, Espinosa A, Flesland O,. Eight years with haemovigilance in Norway. What have we learnt? Transfus Apher Sci 2013; 49: 548-552.
24. Eder AF, Chambers LA,. Noninfectious complications of blood transfusion. Arch Pathol Lab Med 2007; 131: 708-718.
25. Narick C, Triulzi DJ, Yazer MH,. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012; 52: 160-165.
26. Cohn CS, Stubbs J, Schwartz J, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion 2014; 54: 1927-1934.
27. Tobian AA, Fuller AK, Uglik K, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion 2014; 54: 1523-1529; quiz 1522.
28. Faber JC,. The European Blood Directive: a new era of blood regulation has begun. Transfus Med 2004; 14: 257-273.
29. Sickbert-Bennett EE, Weber DJ, Poole C, et al. Completeness of communicable disease reporting, North Carolina, USA, 1995-1997 and 2000-2006. Emerg Infect Dis 2011; 17: 23-29.
30. Lukwago L, Nanyunja M, Ndayimirije N, et al. The implementation of Integrated Disease Surveillance and Response in Uganda: a review of progress and challenges between 2001 and 2007. Health Policy Plan 2013; 28: 30-40.
31. Lin MY, Hota B, Khan YM, et al.; CDC Prevention Epicenter Program. Quality of traditional surveillance for public reporting of nosocomial bloodstream infection rates. JAMA 2010; 304: 2035-2041.
32. Galea S, Tracy M,. Participation rates in epidemiologic studies. Ann Epidemiol 2007; 17: 643-653.
33. Tokars JI, Richards C, Andrus M, et al. The changing face of surveillance for health care-associated infections. Clin Infect Dis 2004; 39: 1347-1352.
34. Backman LA, Melchreit R, Rodriguez R,. Validation of the surveillance and reporting of central line-associated bloodstream infection data to a state health department. Am J Infect Control 2010; 38: 832-838.
35. Backman LA, Nobert G, Melchreit R, et al. Validation of the surveillance and reporting of central line-associated bloodstream infection denominator data. Am J Infect Control 2014; 42: 28-33.
36. Dembek ZF, Kellerman SE, Ganley L, et al. Reporting of vancomycin-resistant enterococci in Connecticut: implementation and validation of a state-based surveillance system. Infect Control Hosp Epidemiol 1999; 20: 671-675.